

Russell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.6	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	4	6.9	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.3	nc	(nc-nc)
Male	5	2.1	238.7	(76.9-557.0)	<u>Ovary</u>				
Female	1	1.6	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.5	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	6	7.1	85.1	(31.1-185.1)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.4	nc	(nc-nc)
Male	2	1.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.4	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.4	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	0.6	nc	(nc-nc)	Male	26	24.1	108.0	(70.5-158.3)
Female	1	0.2	nc	(nc-nc)	Female	17	21.8	78.0	(45.4-124.8)
<u>Lung and Bronchus</u>									
Male	3	3.1	nc	(nc-nc)					
Female	1	2.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rutland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	7.0	71.4	(23.0-166.5)	Male	4	4.9	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	5	3.1	161.4	(52.0-376.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.6	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	3	4.4	nc	(nc-nc)
Female	25	21.4	116.8	(75.5-172.4)	Female	3	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.0	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.0	nc	(nc-nc)
Male	7	8.6	81.0	(32.4-166.9)	<u>Ovary</u>				
Female	10	5.2	193.0	(92.4-355.0)	Female	3	1.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.9	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	4	1.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	20	26.5	75.5	(46.1-116.7)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.7	nc	(nc-nc)
Male	5	4.1	122.0	(39.3-284.8)	Female	0	0.6	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.2	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<u>Leukemia</u>					Female	11	4.8	227.5	(113.4-407.0)
Male	0	2.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.4	nc	(nc-nc)	Female	5	4.6	109.7	(35.4-256.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.1	nc	(nc-nc)	Male	70	97.4	71.8	(56.0-90.8)
Female	0	0.5	nc	(nc-nc)	Female	83	67.6	122.7	(97.7-152.1)
<u>Lung and Bronchus</u>									
Male	10	12.9	77.8	(37.2-143.1)					
Female	9	8.2	109.7	(50.1-208.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	47	39.6	118.7	(87.2-157.9)	Male	23	26.5	86.8	(55.0-130.2)
Female	24	17.3	139.1	(89.1-206.9)	Female	19	24.6	77.1	(46.4-120.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	7.9	75.7	(27.6-164.8)	Male	2	6.6	nc	(nc-nc)
Female	5	7.7	64.6	(20.8-150.8)	Female	5	6.2	81.0	(26.1-189.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.2	nc	(nc-nc)	Male	30	23.2	129.5	(87.4-184.9)
Female	195	171.7	113.6	(98.2-130.7)	Female	24	22.1	108.8	(69.7-161.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	6.8	117.0	(50.4-230.6)	Male	16	16.0	99.8	(57.0-162.1)
<u>Colon / Rectum</u>					Female	8	8.7	91.4	(39.4-180.2)
Male	45	48.1	93.5	(68.2-125.1)	<u>Ovary</u>				
Female	65	56.9	114.3	(88.2-145.7)	Female	13	16.9	76.8	(40.9-131.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	15	10.4	144.3	(80.7-238.0)	Male	14	12.8	109.6	(59.9-183.9)
Female	2	3.5	nc	(nc-nc)	Female	21	16.4	128.2	(79.3-195.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	3.8	nc	(nc-nc)	Male	145	150.4	96.4	(81.4-113.5)
Female	5	3.4	148.1	(47.7-345.7)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	11	9.2	119.2	(59.4-213.3)
Male	29	21.4	135.2	(90.5-194.2)	Female	8	6.6	120.4	(51.8-237.3)
Female	11	14.5	75.8	(37.8-135.5)	<u>Testis</u>				
<u>Larynx</u>					Male	3	6.6	nc	(nc-nc)
Male	11	6.1	181.5	(90.5-324.7)	<u>Thyroid</u>				
Female	4	2.1	nc	(nc-nc)	Male	10	8.9	112.1	(53.7-206.3)
<u>Leukemia</u>					Female	28	31.5	88.8	(59.0-128.3)
Male	24	14.9	160.8	(103.0-239.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	13.0	76.9	(36.8-141.5)	Female	40	40.0	100.1	(71.5-136.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	11.4	96.2	(48.0-172.2)	Male	603	538.2	112.0	(103.3-121.4)
Female	5	4.6	107.9	(34.8-251.7)	Female	635	610.2	104.1	(96.1-112.5)
<u>Lung and Bronchus</u>									
Male	100	71.9	139.0	(113.1-169.1)					
Female	79	86.3	91.5	(72.5-114.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Salisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	9.6	165.9	(94.8-269.5)	Male	9	6.6	135.9	(62.0-258.0)
Female	4	3.8	nc	(nc-nc)	Female	5	5.5	91.1	(29.3-212.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.9	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	6	5.6	106.3	(38.8-231.4)
Female	40	41.2	97.0	(69.3-132.2)	Female	6	5.0	120.5	(44.0-262.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	1.5	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	2.0	nc	(nc-nc)
Male	10	11.9	83.7	(40.1-153.9)	<u>Ovary</u>				
Female	14	12.4	113.2	(61.8-190.0)	Female	3	3.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.7	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	2	3.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	34	40.9	83.1	(57.6-116.2)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.3	nc	(nc-nc)
Male	10	5.7	176.5	(84.5-324.6)	Female	3	1.4	nc	(nc-nc)
Female	3	3.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.1	nc	(nc-nc)
Male	5	1.6	311.9	(100.5-727.8)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
<u>Leukemia</u>					Female	3	7.1	nc	(nc-nc)
Male	0	3.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.7	nc	(nc-nc)	Female	12	9.4	127.0	(65.6-221.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.1	nc	(nc-nc)	Male	141	137.2	102.8	(86.5-121.2)
Female	2	1.0	nc	(nc-nc)	Female	148	140.5	105.4	(89.1-123.8)
<u>Lung and Bronchus</u>									
Male	18	18.6	96.9	(57.4-153.2)					
Female	31	20.6	150.5	(102.3-213.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sandisfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.3	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	4.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.2	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.2	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	5.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.6	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.3	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	6	17.6	34.1	(12.5-74.3)
Female	1	0.1	nc	(nc-nc)	Female	9	14.0	64.4	(29.4-122.3)
<u>Lung and Bronchus</u>									
Male	2	2.5	nc	(nc-nc)					
Female	1	2.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sandwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	29	21.5	134.9	(90.3-193.8)	Male	25	14.7	170.3	(110.2-251.4)
Female	10	7.5	132.9	(63.6-244.4)	Female	20	11.4	175.9	(107.4-271.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	4.3	184.9	(79.6-364.3)	Male	7	3.7	188.7	(75.6-388.8)
Female	7	3.5	199.7	(80.0-411.5)	Female	2	2.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.6	nc	(nc-nc)	Male	13	12.8	101.7	(54.1-173.9)
Female	98	84.7	115.8	(94.0-141.1)	Female	13	9.9	130.9	(69.6-223.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.3	nc	(nc-nc)	Male	9	9.5	94.9	(43.3-180.1)
<u>Colon / Rectum</u>					Female	6	4.1	147.7	(53.9-321.4)
Male	30	26.9	111.5	(75.2-159.1)	<u>Ovary</u>				
Female	22	25.0	87.9	(55.1-133.1)	Female	11	7.9	138.4	(69.0-247.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	6.0	83.4	(26.9-194.7)	Male	8	7.1	112.6	(48.5-221.8)
Female	1	1.5	nc	(nc-nc)	Female	6	7.1	85.0	(31.1-185.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.7	nc	(nc-nc)	Male	127	88.1	144.2	(120.2-171.6)
Female	0	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	5.1	97.9	(31.5-228.4)
Male	11	12.4	88.6	(44.2-158.6)	Female	2	2.8	nc	(nc-nc)
Female	9	6.8	133.2	(60.8-252.8)	<u>Testis</u>				
<u>Larynx</u>					Male	5	2.6	194.3	(62.6-453.4)
Male	4	3.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.0	nc	(nc-nc)	Male	4	4.9	nc	(nc-nc)
<u>Leukemia</u>					Female	8	15.2	52.7	(22.7-103.9)
Male	17	8.1	210.7	(122.7-337.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	5.7	87.5	(28.2-204.3)	Female	21	19.2	109.5	(67.8-167.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	6.8	nc	(nc-nc)	Male	372	302.8	122.8	(110.7-136.0)
Female	3	2.1	nc	(nc-nc)	Female	311	283.4	109.7	(97.9-122.6)
<u>Lung and Bronchus</u>									
Male	31	40.4	76.7	(52.1-108.9)					
Female	38	39.0	97.4	(68.9-133.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Saugus

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	51	31.2	163.6	(121.8-215.1)	Male	11	20.5	53.6	(26.7-95.9)
Female	9	12.8	70.2	(32.0-133.2)	Female	16	17.4	91.9	(52.5-149.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	5.9	nc	(nc-nc)	Male	6	5.2	115.3	(42.1-250.9)
Female	11	5.4	203.1	(101.3-363.5)	Female	5	4.6	107.9	(34.8-251.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	18	17.6	102.0	(60.4-161.2)
Female	147	129.4	113.6	(96.0-133.6)	Female	21	16.4	128.1	(79.2-195.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	4.7	nc	(nc-nc)	Male	16	12.6	127.0	(72.6-206.3)
<u>Colon / Rectum</u>					Female	7	6.5	107.5	(43.1-221.5)
Male	42	37.3	112.7	(81.2-152.3)	<u>Ovary</u>				
Female	41	41.1	99.7	(71.5-135.2)	Female	11	12.5	87.9	(43.8-157.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	8.4	95.8	(41.2-188.7)	Male	8	10.2	78.5	(33.8-154.8)
Female	3	2.7	nc	(nc-nc)	Female	16	12.1	132.6	(75.7-215.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.5	nc	(nc-nc)	Male	118	122.4	96.4	(79.8-115.5)
Female	2	2.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	7.2	139.3	(66.7-256.1)
Male	29	16.9	171.5	(114.8-246.4)	Female	2	4.7	nc	(nc-nc)
Female	13	11.1	117.5	(62.5-201.0)	<u>Testis</u>				
<u>Larynx</u>					Male	10	4.1	245.6	(117.6-451.7)
Male	5	4.8	103.6	(33.4-241.7)	<u>Thyroid</u>				
Female	4	1.6	nc	(nc-nc)	Male	9	6.6	135.4	(61.8-257.0)
<u>Leukemia</u>					Female	21	21.6	97.1	(60.1-148.5)
Male	12	11.2	107.3	(55.4-187.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	9.1	109.7	(52.5-201.7)	Female	30	30.6	98.1	(66.1-140.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	12	9.2	131.0	(67.6-228.9)	Male	485	423.8	114.4	(104.5-125.1)
Female	1	3.5	nc	(nc-nc)	Female	487	453.0	107.5	(98.2-117.5)
<u>Lung and Bronchus</u>									
Male	77	58.0	132.7	(104.7-165.8)					
Female	77	67.6	113.9	(89.9-142.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Savoy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	2.8	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.3	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
Female	1	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	2	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.5	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	14	14.9	94.0	(51.4-157.8)
Female	0	0.1	nc	(nc-nc)	Female	5	9.3	53.5	(17.3-124.9)
<u>Lung and Bronchus</u>									
Male	3	2.1	nc	(nc-nc)					
Female	0	1.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Scituate

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	30	21.5	139.4	(94.0-199.0)	Male	42	13.8	305.2	(219.9-412.6)
Female	7	8.9	78.7	(31.5-162.1)	Female	25	11.8	211.3	(136.7-312.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.9	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
Female	3	3.8	nc	(nc-nc)	Female	7	3.2	218.5	(87.5-450.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	16	12.0	133.7	(76.4-217.2)
Female	102	89.5	113.9	(92.9-138.3)	Female	12	11.3	106.3	(54.9-185.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	3.2	nc	(nc-nc)	Male	19	8.4	227.0	(136.6-354.4)
<u>Colon / Rectum</u>					Female	4	4.4	nc	(nc-nc)
Male	26	25.7	101.2	(66.1-148.3)	<u>Ovary</u>				
Female	25	28.9	86.4	(55.9-127.6)	Female	6	8.5	70.4	(25.7-153.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	5.6	nc	(nc-nc)	Male	2	7.0	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)	Female	10	8.4	118.6	(56.8-218.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.5	nc	(nc-nc)	Male	85	81.7	104.0	(83.1-128.6)
Female	3	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	5.0	nc	(nc-nc)
Male	7	11.3	62.1	(24.9-127.9)	Female	2	3.3	nc	(nc-nc)
Female	6	7.6	78.8	(28.8-171.6)	<u>Testis</u>				
<u>Larynx</u>					Male	5	2.2	226.2	(72.9-527.9)
Male	3	3.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.1	nc	(nc-nc)	Male	5	4.3	117.0	(37.7-273.1)
<u>Leukemia</u>					Female	14	14.3	97.7	(53.4-163.9)
Male	12	7.8	153.2	(79.1-267.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	6.5	124.0	(53.4-244.4)	Female	17	20.6	82.5	(48.1-132.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	6.0	nc	(nc-nc)	Male	332	286.2	116.0	(103.9-129.2)
Female	2	2.4	nc	(nc-nc)	Female	321	312.1	102.9	(91.9-114.8)
<u>Lung and Bronchus</u>									
Male	34	39.4	86.4	(59.8-120.7)					
Female	53	46.4	114.3	(85.6-149.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Seekonk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	16.3	110.7	(65.6-175.0)	Male	16	10.5	152.6	(87.2-247.9)
Female	2	5.6	nc	(nc-nc)	Female	3	8.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.0	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
Female	0	2.5	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	10	9.1	109.7	(52.5-201.8)
Female	69	60.0	115.0	(89.5-145.5)	Female	6	7.4	81.4	(29.7-177.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.3	nc	(nc-nc)	Male	7	6.4	108.6	(43.5-223.7)
<u>Colon / Rectum</u>					Female	0	2.9	nc	(nc-nc)
Male	14	19.5	71.7	(39.2-120.3)	<u>Ovary</u>				
Female	17	18.4	92.3	(53.8-147.8)	Female	4	5.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	4.3	116.9	(37.7-272.9)	Male	4	5.2	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	7	5.3	131.4	(52.6-270.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.2	nc	(nc-nc)	Male	59	61.9	95.2	(72.5-122.9)
Female	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	3.8	132.9	(42.8-310.1)
Male	8	8.8	90.7	(39.0-178.7)	Female	1	2.1	nc	(nc-nc)
Female	6	5.0	119.3	(43.6-259.7)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.8	nc	(nc-nc)
Male	3	2.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	5	3.3	149.3	(48.1-348.4)
<u>Leukemia</u>					Female	13	10.5	123.9	(65.9-211.8)
Male	5	5.8	86.5	(27.9-201.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	4.1	121.4	(39.1-283.3)	Female	10	13.7	72.8	(34.8-133.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	4.7	nc	(nc-nc)	Male	204	217.8	93.7	(81.2-107.4)
Female	0	1.6	nc	(nc-nc)	Female	190	206.2	92.2	(79.5-106.2)
<u>Lung and Bronchus</u>									
Male	23	30.3	76.0	(48.1-114.0)					
Female	23	30.0	76.6	(48.5-114.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sharon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	18.8	106.3	(64.9-164.2)	Male	11	13.0	84.8	(42.3-151.8)
Female	3	5.9	nc	(nc-nc)	Female	17	9.2	184.1	(107.2-294.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.8	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	Female	4	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.6	nc	(nc-nc)	Male	21	11.2	187.8	(116.2-287.0)
Female	71	69.2	102.6	(80.1-129.4)	Female	9	7.8	114.9	(52.4-218.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.7	nc	(nc-nc)	Male	5	8.4	59.5	(19.2-138.9)
<u>Colon / Rectum</u>					Female	4	3.3	nc	(nc-nc)
Male	20	23.8	83.9	(51.2-129.5)	<u>Ovary</u>				
Female	22	19.4	113.5	(71.1-171.9)	Female	8	6.4	125.4	(54.0-247.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	5.3	94.8	(30.6-221.3)	Male	7	6.3	111.5	(44.7-229.7)
Female	1	1.2	nc	(nc-nc)	Female	12	5.5	218.1	(112.6-381.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.5	nc	(nc-nc)	Male	72	78.3	92.0	(72.0-115.8)
Female	1	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.5	nc	(nc-nc)
Male	6	11.0	54.6	(19.9-118.8)	Female	0	2.2	nc	(nc-nc)
Female	9	5.4	165.8	(75.6-314.7)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.3	nc	(nc-nc)
Male	3	3.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	7	4.4	160.4	(64.2-330.4)
<u>Leukemia</u>					Female	25	12.7	197.3	(127.7-291.3)
Male	4	7.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	4.5	111.2	(35.8-259.4)	Female	15	15.6	96.3	(53.9-158.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	6.0	nc	(nc-nc)	Male	243	267.6	90.8	(79.7-103.0)
Female	1	1.6	nc	(nc-nc)	Female	263	227.4	115.7	(102.1-130.5)
<u>Lung and Bronchus</u>									
Male	24	35.5	67.5	(43.3-100.5)					
Female	30	30.9	97.1	(65.5-138.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sheffield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	4.9	141.5	(56.7-291.5)	Male	2	3.2	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	2.7	nc	(nc-nc)
Female	27	17.5	154.1	(101.5-224.2)	Female	2	2.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.9	nc	(nc-nc)
Male	2	6.0	nc	(nc-nc)	<u>Ovary</u>				
Female	3	5.2	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.4	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	11	20.8	52.8	(26.3-94.6)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.2	nc	(nc-nc)
Male	1	2.8	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.4	nc	(nc-nc)
Male	2	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.8	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.1	nc	(nc-nc)	Female	0	4.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.5	nc	(nc-nc)	Male	47	68.4	68.7	(50.5-91.4)
Female	1	0.4	nc	(nc-nc)	Female	61	59.2	103.0	(78.8-132.3)
<u>Lung and Bronchus</u>									
Male	8	9.4	85.0	(36.6-167.6)					
Female	11	8.6	127.2	(63.4-227.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shelburne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	3.1	nc	(nc-nc)	Male	5	1.9	266.9	(86.0-622.9)
Female	0	1.3	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	9	11.2	80.7	(36.8-153.2)	Female	3	1.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.6	nc	(nc-nc)
Male	4	3.8	nc	(nc-nc)	<u>Ovary</u>				
Female	2	4.2	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.8	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	12	10.9	110.0	(56.8-192.2)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.7	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.3	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.6	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.9	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.8	nc	(nc-nc)	Male	37	39.4	93.8	(66.0-129.3)
Female	0	0.3	nc	(nc-nc)	Female	28	40.9	68.5	(45.5-99.0)
<u>Lung and Bronchus</u>									
Male	4	5.4	nc	(nc-nc)					
Female	1	6.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sherborn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	4.8	nc	(nc-nc)	Male	7	3.2	221.7	(88.8-456.9)
Female	0	1.7	nc	(nc-nc)	Female	4	2.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	0.9	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	20	19.5	102.3	(62.5-158.1)	Female	1	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.9	nc	(nc-nc)
Male	9	5.9	153.8	(70.2-292.0)	<u>Ovary</u>				
Female	3	5.6	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	1.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	17	19.4	87.7	(51.0-140.3)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.1	nc	(nc-nc)
Male	1	2.6	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	4	3.3	nc	(nc-nc)
Male	4	1.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.3	nc	(nc-nc)	Female	5	4.4	113.2	(36.5-264.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.4	nc	(nc-nc)	Male	67	66.4	101.0	(78.2-128.2)
Female	0	0.5	nc	(nc-nc)	Female	59	64.3	91.8	(69.9-118.4)
<u>Lung and Bronchus</u>									
Male	1	9.0	nc	(nc-nc)					
Female	6	9.0	66.7	(24.4-145.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shirley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	6.7	74.3	(24.0-173.4)	Male	6	5.2	116.2	(42.4-253.0)
Female	3	2.4	nc	(nc-nc)	Female	2	3.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.7	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	4.4	nc	(nc-nc)
Female	17	25.2	67.5	(39.3-108.1)	Female	0	3.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	1	3.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.2	nc	(nc-nc)
Male	8	8.7	91.5	(39.4-180.3)	<u>Ovary</u>				
Female	9	8.5	105.4	(48.1-200.0)	Female	0	2.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.8	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	5	2.3	213.2	(68.7-497.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.9	nc	(nc-nc)	Male	31	25.7	120.5	(81.8-171.0)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	1.6	nc	(nc-nc)
Male	7	4.2	167.2	(67.0-344.5)	Female	1	1.0	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.9	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<u>Leukemia</u>					Female	3	4.7	nc	(nc-nc)
Male	3	2.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.9	nc	(nc-nc)	Female	6	5.5	109.6	(40.0-238.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.2	nc	(nc-nc)	Male	109	97.4	111.9	(91.9-135.0)
Female	0	0.7	nc	(nc-nc)	Female	74	88.5	83.6	(65.6-104.9)
<u>Lung and Bronchus</u>									
Male	21	12.2	171.6	(106.2-262.3)					
Female	17	12.1	140.9	(82.0-225.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shrewsbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	38	30.9	123.0	(87.0-168.8)	Male	20	21.0	95.2	(58.1-147.0)
Female	13	12.8	101.3	(53.9-173.3)	Female	20	18.5	108.2	(66.1-167.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	6.5	154.1	(73.8-283.4)	Male	8	5.1	157.3	(67.7-309.9)
Female	6	5.8	103.2	(37.7-224.7)	Female	4	4.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.9	nc	(nc-nc)	Male	28	18.5	151.7	(100.8-219.2)
Female	135	130.5	103.5	(86.7-122.4)	Female	14	16.5	84.6	(46.2-142.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	5.3	nc	(nc-nc)	Male	12	12.7	94.1	(48.6-164.4)
<u>Colon / Rectum</u>					Female	4	6.5	nc	(nc-nc)
Male	34	38.0	89.4	(61.9-124.9)	<u>Ovary</u>				
Female	47	42.9	109.6	(80.5-145.8)	Female	13	12.4	104.5	(55.6-178.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	8.0	162.3	(86.3-277.5)	Male	14	10.0	140.4	(76.7-235.6)
Female	1	2.6	nc	(nc-nc)	Female	8	12.2	65.4	(28.1-128.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	3.0	nc	(nc-nc)	Male	117	113.3	103.2	(85.4-123.7)
Female	5	2.5	203.1	(65.4-473.9)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	7.3	68.5	(22.1-159.9)
Male	24	17.3	138.9	(89.0-206.7)	Female	3	5.0	nc	(nc-nc)
Female	10	10.8	92.6	(44.3-170.4)	<u>Testis</u>				
<u>Larynx</u>					Male	10	5.1	194.4	(93.1-357.5)
Male	3	4.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.5	nc	(nc-nc)	Male	6	7.3	82.2	(30.0-178.9)
<u>Leukemia</u>					Female	16	24.1	66.3	(37.9-107.7)
Male	15	11.9	125.6	(70.3-207.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	9.8	61.0	(22.3-132.8)	Female	26	28.7	90.7	(59.3-133.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	8.9	56.0	(18.0-130.6)	Male	455	419.2	108.5	(98.8-119.0)
Female	0	3.4	nc	(nc-nc)	Female	416	457.4	90.9	(82.4-100.1)
<u>Lung and Bronchus</u>									
Male	52	56.1	92.8	(69.3-121.6)					
Female	55	63.9	86.1	(64.8-112.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shutesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.7	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	9	8.2	109.4	(49.9-207.7)	Female	0	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	3	2.3	nc	(nc-nc)	<u>Ovary</u>				
Female	2	1.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	8.4	83.2	(33.3-171.4)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.4	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.6	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.7	nc	(nc-nc)	Male	21	27.0	77.9	(48.2-119.1)
Female	0	0.2	nc	(nc-nc)	Female	19	24.9	76.4	(46.0-119.3)
<u>Lung and Bronchus</u>									
Male	3	3.3	nc	(nc-nc)					
Female	2	3.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Somerset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	25.0	104.2	(68.0-152.6)	Male	13	15.6	83.2	(44.2-142.2)
Female	11	12.3	89.3	(44.5-159.8)	Female	5	13.7	36.5	(11.8-85.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	4.3	116.3	(37.5-271.5)	Male	4	4.1	nc	(nc-nc)
Female	4	4.2	nc	(nc-nc)	Female	4	4.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	19	13.6	140.0	(84.3-218.7)
Female	78	99.9	78.0	(61.7-97.4)	Female	12	14.6	81.9	(42.3-143.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	3.3	151.1	(48.7-352.6)	Male	7	9.4	74.3	(29.7-153.0)
<u>Colon / Rectum</u>					Female	4	5.4	nc	(nc-nc)
Male	35	29.6	118.3	(82.4-164.5)	<u>Ovary</u>				
Female	25	41.8	59.8	(38.7-88.3)	Female	14	10.2	137.7	(75.2-231.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	6.4	125.6	(54.1-247.6)	Male	13	8.0	161.8	(86.1-276.8)
Female	1	2.5	nc	(nc-nc)	Female	8	12.0	66.5	(28.6-131.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.7	nc	(nc-nc)	Male	99	91.9	107.7	(87.5-131.1)
Female	1	1.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	11	5.7	192.7	(96.0-344.7)
Male	13	12.7	102.1	(54.3-174.5)	Female	10	5.0	198.5	(95.0-365.1)
Female	6	8.8	68.1	(24.9-148.2)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.5	nc	(nc-nc)
Male	2	3.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.2	nc	(nc-nc)	Male	0	4.7	nc	(nc-nc)
<u>Leukemia</u>					Female	12	14.4	83.5	(43.1-145.8)
Male	10	8.8	114.0	(54.6-209.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	8.4	118.4	(56.7-217.7)	Female	23	21.9	105.2	(66.7-157.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	6.9	87.3	(31.9-189.9)	Male	349	325.3	107.3	(96.3-119.2)
Female	3	3.1	nc	(nc-nc)	Female	311	380.0	81.8	(73.0-91.5)
<u>Lung and Bronchus</u>									
Male	46	45.2	101.9	(74.6-135.9)					
Female	43	56.9	75.6	(54.7-101.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Somerville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	42	52.3	80.4	(57.9-108.6)	Male	31	38.4	80.7	(54.8-114.6)
Female	24	23.8	101.0	(64.7-150.2)	Female	25	39.9	62.7	(40.6-92.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	12.5	72.3	(33.0-137.2)	Male	7	8.7	80.1	(32.1-165.1)
Female	11	12.0	91.5	(45.6-163.7)	Female	9	8.5	105.9	(48.3-201.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	1.5	nc	(nc-nc)	Male	31	33.4	92.9	(63.1-131.8)
Female	205	240.6	85.2	(73.9-97.7)	Female	23	31.7	72.6	(46.0-108.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	11.4	61.4	(24.6-126.4)	Male	33	22.3	147.9	(101.8-207.7)
<u>Colon / Rectum</u>					Female	11	12.3	89.2	(44.4-159.5)
Male	68	64.8	104.9	(81.5-133.0)	<u>Ovary</u>				
Female	82	80.5	101.8	(81.0-126.4)	Female	15	24.0	62.5	(35.0-103.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	13.8	93.9	(50.0-160.6)	Male	25	16.9	148.0	(95.8-218.5)
Female	10	4.9	205.6	(98.4-378.1)	Female	18	22.7	79.4	(47.0-125.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	12	8.4	143.2	(73.9-250.2)	Male	159	197.4	80.5	(68.5-94.1)
Female	4	7.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	18	12.3	146.1	(86.5-230.9)
Male	25	29.9	83.6	(54.1-123.5)	Female	11	9.3	118.0	(58.8-211.1)
Female	14	20.4	68.5	(37.4-114.9)	<u>Testis</u>				
<u>Larynx</u>					Male	8	16.7	47.8	(20.6-94.3)
Male	11	8.1	136.5	(68.0-244.2)	<u>Thyroid</u>				
Female	4	2.8	nc	(nc-nc)	Male	18	15.0	119.9	(71.0-189.5)
<u>Leukemia</u>					Female	61	55.5	109.9	(84.0-141.1)
Male	15	20.8	72.0	(40.3-118.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	23	18.7	123.1	(78.0-184.7)	Female	43	53.2	80.9	(58.5-108.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	22	15.8	139.3	(87.3-210.9)	Male	719	741.5	97.0	(90.0-104.3)
Female	6	6.6	91.1	(33.3-198.4)	Female	780	874.9	89.2	(83.0-95.6)
<u>Lung and Bronchus</u>									
Male	119	95.4	124.8	(103.4-149.3)					
Female	113	118.2	95.6	(78.8-114.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

South Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	28	24.1	116.0	(77.0-167.6)	Male	17	14.5	117.0	(68.1-187.4)
Female	11	8.7	126.8	(63.2-226.9)	Female	11	11.1	99.3	(49.5-177.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.9	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
Female	3	3.5	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	13	12.7	102.7	(54.6-175.6)
Female	108	78.3	138.0	(113.2-166.6)	Female	9	10.9	82.9	(37.8-157.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.7	nc	(nc-nc)	Male	7	8.4	82.8	(33.2-170.7)
<u>Colon / Rectum</u>					Female	5	4.1	122.2	(39.4-285.1)
Male	30	28.1	106.7	(72.0-152.3)	<u>Ovary</u>				
Female	19	28.4	67.0	(40.3-104.6)	Female	10	7.9	127.3	(60.9-234.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	5.9	nc	(nc-nc)	Male	6	7.6	78.5	(28.7-170.9)
Female	1	1.8	nc	(nc-nc)	Female	7	8.3	84.3	(33.8-173.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.4	nc	(nc-nc)	Male	78	84.6	92.2	(72.9-115.0)
Female	1	1.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	5.4	110.4	(40.3-240.3)
Male	11	11.7	94.1	(46.9-168.3)	Female	4	3.3	nc	(nc-nc)
Female	4	7.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	2.1	nc	(nc-nc)
Male	6	3.4	176.0	(64.3-383.0)	<u>Thyroid</u>				
Female	0	1.0	nc	(nc-nc)	Male	1	4.1	nc	(nc-nc)
<u>Leukemia</u>					Female	11	12.7	86.5	(43.1-154.9)
Male	9	8.3	108.9	(49.7-206.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	6.2	81.2	(26.2-189.4)	Female	24	18.0	133.6	(85.6-198.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	6.3	nc	(nc-nc)	Male	292	304.5	95.9	(85.2-107.6)
Female	0	2.3	nc	(nc-nc)	Female	297	288.6	102.9	(91.5-115.3)
<u>Lung and Bronchus</u>									
Male	44	43.3	101.5	(73.8-136.3)					
Female	39	44.0	88.6	(63.0-121.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	7.1	nc	(nc-nc)	Male	5	4.6	108.7	(35.0-253.7)
Female	4	2.1	nc	(nc-nc)	Female	2	3.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.3	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
Female	24	25.5	94.0	(60.2-139.9)	Female	4	2.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.2	nc	(nc-nc)
Male	5	8.2	60.7	(19.6-141.7)	<u>Ovary</u>				
Female	5	6.8	73.1	(23.5-170.5)	Female	5	2.4	211.1	(68.0-492.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.9	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	31	27.1	114.2	(77.6-162.1)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.6	nc	(nc-nc)
Male	3	3.9	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.8	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	1	4.6	nc	(nc-nc)
Male	0	2.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.6	nc	(nc-nc)	Female	5	6.0	83.2	(26.8-194.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.0	nc	(nc-nc)	Male	78	94.8	82.3	(65.1-102.7)
Female	0	0.6	nc	(nc-nc)	Female	70	83.2	84.1	(65.5-106.2)
<u>Lung and Bronchus</u>									
Male	7	13.2	53.1	(21.3-109.4)					
Female	6	11.5	52.4	(19.1-114.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	10.2	128.0	(68.1-219.0)	Male	11	6.9	158.7	(79.1-283.9)
Female	2	3.0	nc	(nc-nc)	Female	4	4.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.1	nc	(nc-nc)	Male	5	1.7	289.7	(93.4-676.1)
Female	1	1.6	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	6.1	nc	(nc-nc)
Female	36	36.4	98.9	(69.2-136.9)	Female	3	4.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.4	nc	(nc-nc)	Male	7	4.4	157.5	(63.1-324.6)
<u>Colon / Rectum</u>					Female	1	1.7	nc	(nc-nc)
Male	8	12.6	63.6	(27.4-125.3)	<u>Ovary</u>				
Female	12	10.2	117.8	(60.8-205.9)	Female	2	3.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.8	nc	(nc-nc)	Male	6	3.3	181.5	(66.3-395.1)
Female	0	0.6	nc	(nc-nc)	Female	6	2.8	211.0	(77.0-459.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	43	40.8	105.3	(76.2-141.8)
Female	2	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	2.4	nc	(nc-nc)
Male	4	5.9	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Female	0	2.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.2	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	5	2.3	213.8	(68.9-498.9)
<u>Leukemia</u>					Female	2	6.8	nc	(nc-nc)
Male	6	3.8	157.8	(57.6-343.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.4	nc	(nc-nc)	Female	11	8.4	131.4	(65.5-235.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	3.2	nc	(nc-nc)	Male	154	142.1	108.3	(91.9-126.9)
Female	0	0.9	nc	(nc-nc)	Female	120	119.7	100.2	(83.1-119.9)
<u>Lung and Bronchus</u>									
Male	13	19.1	68.1	(36.2-116.4)					
Female	21	15.9	131.7	(81.5-201.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	17.8	129.2	(81.9-193.8)	Male	7	11.6	60.4	(24.2-124.4)
Female	7	6.7	103.7	(41.6-213.8)	Female	0	9.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.4	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	1	3.1	nc	(nc-nc)	Female	0	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	8	10.2	78.5	(33.8-154.7)
Female	63	65.6	96.0	(73.8-122.9)	Female	7	8.6	81.2	(32.5-167.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.6	nc	(nc-nc)	Male	8	7.1	113.0	(48.6-222.6)
<u>Colon / Rectum</u>					Female	4	3.3	nc	(nc-nc)
Male	33	21.2	156.0	(107.4-219.1)	<u>Ovary</u>				
Female	23	23.1	99.6	(63.1-149.5)	Female	2	6.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	4.7	107.1	(34.5-250.0)	Male	8	5.7	140.0	(60.3-275.9)
Female	1	1.4	nc	(nc-nc)	Female	5	6.5	77.0	(24.8-179.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.6	nc	(nc-nc)	Male	45	67.5	66.7	(48.6-89.2)
Female	1	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	4.1	122.2	(39.4-285.3)
Male	9	9.4	95.4	(43.5-181.0)	Female	4	2.7	nc	(nc-nc)
Female	9	5.5	164.3	(75.0-311.9)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.6	nc	(nc-nc)
Male	3	2.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
<u>Leukemia</u>					Female	9	12.2	73.7	(33.6-140.0)
Male	11	6.6	167.1	(83.3-299.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	5.3	151.3	(65.1-298.1)	Female	16	14.4	111.3	(63.6-180.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	5.1	nc	(nc-nc)	Male	218	238.6	91.3	(79.6-104.3)
Female	1	1.8	nc	(nc-nc)	Female	213	235.5	90.4	(78.7-103.4)
<u>Lung and Bronchus</u>									
Male	23	32.1	71.6	(45.3-107.4)					
Female	33	32.3	102.2	(70.3-143.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	11.1	99.1	(49.4-177.3)	Male	2	7.3	nc	(nc-nc)
Female	3	4.2	nc	(nc-nc)	Female	4	5.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.1	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	6.4	nc	(nc-nc)
Female	42	42.2	99.4	(71.7-134.4)	Female	5	5.4	93.1	(30.0-217.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.6	nc	(nc-nc)	Male	4	4.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	2.1	nc	(nc-nc)
Male	12	13.1	91.3	(47.1-159.4)	<u>Ovary</u>				
Female	21	14.3	147.2	(91.1-225.0)	Female	4	4.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.9	nc	(nc-nc)	Male	5	3.6	139.4	(44.9-325.4)
Female	0	0.9	nc	(nc-nc)	Female	1	4.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.9	nc	(nc-nc)	Male	45	41.1	109.6	(79.9-146.6)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.6	nc	(nc-nc)
Male	3	6.0	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
Female	1	3.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.4	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.5	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
<u>Leukemia</u>					Female	4	7.3	nc	(nc-nc)
Male	1	4.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.1	nc	(nc-nc)	Female	12	9.4	127.1	(65.6-222.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.2	nc	(nc-nc)	Male	127	147.9	85.9	(71.6-102.2)
Female	2	1.1	nc	(nc-nc)	Female	136	147.6	92.1	(77.3-109.0)
<u>Lung and Bronchus</u>									
Male	12	20.2	59.4	(30.6-103.7)					
Female	18	20.3	88.6	(52.5-140.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Spencer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	14.4	97.0	(53.0-162.7)	Male	2	9.6	nc	(nc-nc)
Female	4	4.7	nc	(nc-nc)	Female	2	6.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.7	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	7	8.2	85.2	(34.1-175.5)
Female	43	49.9	86.1	(62.3-116.0)	Female	6	6.2	97.0	(35.4-211.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.9	nc	(nc-nc)	Male	1	6.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	2.5	nc	(nc-nc)
Male	19	17.5	108.7	(65.4-169.8)	<u>Ovary</u>				
Female	24	15.7	153.1	(98.1-227.9)	Female	2	4.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	4.0	nc	(nc-nc)	Male	4	4.7	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	2	4.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	29	61.3	47.3	(31.7-67.9)
Female	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.4	nc	(nc-nc)
Male	6	8.1	73.9	(27.0-160.8)	Female	1	1.8	nc	(nc-nc)
Female	8	4.1	195.3	(84.1-384.9)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.8	nc	(nc-nc)
Male	4	2.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
<u>Leukemia</u>					Female	3	8.8	nc	(nc-nc)
Male	8	5.1	156.9	(67.5-309.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	3.6	166.8	(60.9-363.0)	Female	12	11.7	103.0	(53.1-179.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.4	nc	(nc-nc)	Male	139	202.6	68.6	(57.7-81.0)
Female	1	1.3	nc	(nc-nc)	Female	156	172.5	90.4	(76.8-105.8)
<u>Lung and Bronchus</u>									
Male	18	27.4	65.8	(39.0-103.9)					
Female	21	24.0	87.3	(54.0-133.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	87	127.4	68.3	(54.7-84.2)	Male	40	86.7	46.2	(33.0-62.9)
Female	50	51.8	96.6	(71.7-127.3)	Female	41	78.7	52.1	(37.4-70.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	19	27.2	69.7	(42.0-108.9)	Male	22	21.4	103.0	(64.5-155.9)
Female	18	25.5	70.7	(41.9-111.7)	Female	18	18.8	95.8	(56.7-151.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	8	3.8	212.5	(91.5-418.8)	Male	60	76.4	78.5	(59.9-101.1)
Female	528	543.7	97.1	(89.0-105.8)	Female	57	68.5	83.3	(63.1-107.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	29	22.0	131.7	(88.2-189.1)	Male	64	53.0	120.7	(92.9-154.1)
<u>Colon / Rectum</u>					Female	22	27.1	81.1	(50.8-122.7)
Male	161	156.5	102.9	(87.6-120.0)	<u>Ovary</u>				
Female	150	171.5	87.4	(74.0-102.6)	Female	41	52.5	78.1	(56.1-106.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	32	34.0	94.1	(64.3-132.8)	Male	43	41.4	104.0	(75.2-140.1)
Female	9	10.7	84.4	(38.5-160.2)	Female	35	49.0	71.5	(49.8-99.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	18	13.8	130.5	(77.3-206.2)	Male	493	494.7	99.7	(91.1-108.9)
Female	10	12.0	83.3	(39.9-153.1)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	53	29.8	177.7	(133.1-232.4)
Male	84	70.7	118.9	(94.8-147.2)	Female	25	19.6	127.7	(82.6-188.6)
Female	45	45.4	99.1	(72.3-132.6)	<u>Testis</u>				
<u>Larynx</u>					Male	15	23.0	65.1	(36.4-107.5)
Male	24	19.8	120.9	(77.4-179.9)	<u>Thyroid</u>				
Female	6	6.4	94.1	(34.4-204.9)	Male	16	29.8	53.7	(30.6-87.1)
<u>Leukemia</u>					Female	72	104.5	68.9	(53.9-86.7)
Male	39	50.0	78.0	(55.4-106.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	35	40.9	85.7	(59.7-119.1)	Female	116	123.7	93.8	(77.5-112.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	43	38.1	112.9	(81.7-152.1)	Male	1712	1766.6	96.9	(92.4-101.6)
Female	16	14.5	110.6	(63.2-179.6)	Female	1729	1902.3	90.9	(86.7-95.3)
<u>Lung and Bronchus</u>									
Male	270	234.8	115.0	(101.7-129.6)					
Female	263	265.5	99.0	(87.4-111.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sterling

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	8.0	138.2	(68.9-247.3)	Male	7	5.5	127.9	(51.2-263.5)
Female	5	3.0	164.4	(53.0-383.6)	Female	7	4.5	155.6	(62.4-320.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	8	4.8	167.0	(71.9-329.1)
Female	26	33.6	77.4	(50.5-113.4)	Female	4	4.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.3	nc	(nc-nc)	Male	6	3.5	169.7	(62.0-369.4)
<u>Colon / Rectum</u>					Female	0	1.6	nc	(nc-nc)
Male	6	9.9	60.9	(22.2-132.6)	<u>Ovary</u>				
Female	11	9.9	110.8	(55.2-198.2)	Female	5	3.1	159.1	(51.3-371.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	2.2	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	4	2.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	31	31.7	97.7	(66.4-138.6)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	1.9	nc	(nc-nc)
Male	3	4.7	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Female	7	2.7	255.7	(102.4-526.8)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.1	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
<u>Leukemia</u>					Female	3	5.9	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	2.3	nc	(nc-nc)	Female	5	7.7	64.8	(20.9-151.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.6	nc	(nc-nc)	Male	101	111.5	90.6	(73.8-110.1)
Female	0	0.9	nc	(nc-nc)	Female	99	113.4	87.3	(71.0-106.3)
<u>Lung and Bronchus</u>									
Male	10	15.0	66.6	(31.9-122.4)					
Female	10	16.0	62.4	(29.9-114.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.8	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)
Female	10	7.1	140.1	(67.1-257.7)	Female	2	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	4	3.2	nc	(nc-nc)	<u>Ovary</u>				
Female	1	2.5	nc	(nc-nc)	Female	3	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.7	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	10	9.5	105.7	(50.6-194.3)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.2	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	3	1.2	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	33	34.2	96.6	(66.5-135.7)
Female	0	0.2	nc	(nc-nc)	Female	36	25.9	139.1	(97.4-192.6)
<u>Lung and Bronchus</u>									
Male	5	4.9	101.3	(32.6-236.4)					
Female	7	3.9	180.8	(72.4-372.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stoneham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	30	28.0	107.1	(72.2-152.9)	Male	13	17.6	73.9	(39.3-126.4)
Female	8	11.5	69.5	(29.9-136.9)	Female	17	14.4	117.9	(68.6-188.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	4.9	102.4	(33.0-239.0)	Male	4	4.6	nc	(nc-nc)
Female	4	4.5	nc	(nc-nc)	Female	2	4.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	25	15.3	163.4	(105.7-241.2)
Female	118	105.6	111.8	(92.5-133.9)	Female	13	14.2	91.7	(48.8-156.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	3.8	237.9	(108.5-451.6)	Male	9	10.5	86.1	(39.3-163.5)
<u>Colon / Rectum</u>					Female	10	5.4	184.6	(88.4-339.5)
Male	33	33.3	99.0	(68.1-139.0)	<u>Ovary</u>				
Female	40	38.5	104.0	(74.3-141.6)	Female	11	10.3	106.8	(53.2-191.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	7.1	140.9	(67.5-259.2)	Male	8	9.0	89.3	(38.4-175.9)
Female	4	2.4	nc	(nc-nc)	Female	9	11.1	81.2	(37.1-154.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	2.0	nc	(nc-nc)	Male	107	101.9	105.0	(86.0-126.8)
Female	3	1.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	11	6.4	171.7	(85.6-307.2)
Male	15	14.3	105.1	(58.8-173.3)	Female	4	4.5	nc	(nc-nc)
Female	8	9.1	88.3	(38.0-174.0)	<u>Testis</u>				
<u>Larynx</u>					Male	6	3.0	197.4	(72.1-429.6)
Male	7	4.1	171.0	(68.5-352.3)	<u>Thyroid</u>				
Female	1	1.2	nc	(nc-nc)	Male	5	5.3	93.6	(30.2-218.4)
<u>Leukemia</u>					Female	18	16.8	106.9	(63.3-168.9)
Male	14	9.9	141.1	(77.1-236.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	12	8.2	145.8	(75.3-254.8)	Female	26	23.2	111.9	(73.1-164.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	9	7.8	116.0	(52.9-220.3)	Male	412	364.8	112.9	(102.3-124.4)
Female	3	3.0	nc	(nc-nc)	Female	405	382.2	106.0	(95.9-116.8)
<u>Lung and Bronchus</u>									
Male	64	50.9	125.7	(96.8-160.5)					
Female	57	56.4	101.1	(76.6-131.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stoughton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	37	29.5	125.3	(88.2-172.7)	Male	20	19.5	102.7	(62.7-158.7)
Female	15	12.5	120.1	(67.2-198.0)	Female	17	16.6	102.1	(59.4-163.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.6	107.0	(39.1-232.9)	Male	3	4.9	nc	(nc-nc)
Female	6	5.2	115.4	(42.1-251.2)	Female	6	4.5	134.2	(49.0-292.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.9	nc	(nc-nc)	Male	24	17.0	141.6	(90.7-210.7)
Female	130	121.3	107.1	(89.5-127.2)	Female	22	15.8	139.7	(87.5-211.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	10	4.4	227.9	(109.1-419.2)	Male	21	12.0	175.0	(108.3-267.5)
<u>Colon / Rectum</u>					Female	8	6.1	130.8	(56.3-257.7)
Male	44	36.2	121.7	(88.4-163.4)	<u>Ovary</u>				
Female	43	41.5	103.5	(74.9-139.4)	Female	14	11.8	119.0	(65.0-199.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	7.8	167.4	(89.0-286.3)	Male	17	9.6	177.0	(103.0-283.4)
Female	4	2.6	nc	(nc-nc)	Female	8	11.9	67.0	(28.9-132.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	2.5	nc	(nc-nc)	Male	111	112.6	98.6	(81.1-118.7)
Female	3	2.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	6.9	86.8	(31.7-189.0)
Male	12	16.0	75.1	(38.8-131.2)	Female	9	4.8	187.7	(85.6-356.3)
Female	15	10.3	145.6	(81.4-240.1)	<u>Testis</u>				
<u>Larynx</u>					Male	2	3.9	nc	(nc-nc)
Male	7	4.5	154.8	(62.0-319.0)	<u>Thyroid</u>				
Female	1	1.4	nc	(nc-nc)	Male	9	6.3	142.1	(64.9-269.8)
<u>Leukemia</u>					Female	34	20.2	168.4	(116.6-235.3)
Male	10	11.0	91.2	(43.7-167.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	9.1	120.3	(60.0-215.3)	Female	21	27.2	77.3	(47.8-118.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	8.6	58.3	(18.8-136.0)	Male	450	399.5	112.6	(102.5-123.5)
Female	3	3.3	nc	(nc-nc)	Female	483	431.1	112.1	(102.3-122.5)
<u>Lung and Bronchus</u>									
Male	70	53.9	129.8	(101.1-163.9)					
Female	68	63.0	107.9	(83.8-136.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	6.4	78.4	(25.3-182.9)	Male	6	4.5	133.0	(48.6-289.4)
Female	2	1.7	nc	(nc-nc)	Female	8	3.2	248.9	(107.2-490.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.4	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	6	3.9	153.2	(55.9-333.5)
Female	35	23.9	146.3	(101.9-203.5)	Female	2	2.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	1.1	nc	(nc-nc)
Male	2	7.9	nc	(nc-nc)	<u>Ovary</u>				
Female	9	5.6	161.6	(73.7-306.7)	Female	2	2.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.8	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	30	27.5	109.0	(73.5-155.6)
Female	2	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.5	nc	(nc-nc)
Male	1	3.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	3	1.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.9	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	4	1.6	nc	(nc-nc)
<u>Leukemia</u>					Female	1	4.8	nc	(nc-nc)
Male	3	2.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.4	nc	(nc-nc)	Female	5	5.5	90.3	(29.1-210.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.0	nc	(nc-nc)	Male	79	92.3	85.6	(67.7-106.6)
Female	2	0.5	nc	(nc-nc)	Female	93	74.5	124.9	(100.8-153.0)
<u>Lung and Bronchus</u>									
Male	3	12.1	nc	(nc-nc)					
Female	9	9.5	95.0	(43.3-180.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sturbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	7.9	100.9	(43.5-198.9)	Male	4	5.6	nc	(nc-nc)
Female	4	3.5	nc	(nc-nc)	Female	6	5.2	115.2	(42.0-250.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.7	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	3	1.6	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	4	4.8	nc	(nc-nc)
Female	44	38.8	113.3	(82.3-152.1)	Female	5	4.6	108.4	(34.9-252.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.5	nc	(nc-nc)	Male	0	3.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.9	nc	(nc-nc)
Male	17	9.9	172.5	(100.4-276.2)	<u>Ovary</u>				
Female	9	10.7	84.4	(38.5-160.1)	Female	1	3.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.2	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	39	33.4	116.7	(82.9-159.5)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.9	nc	(nc-nc)
Male	5	4.7	105.9	(34.1-247.2)	Female	1	1.2	nc	(nc-nc)
Female	7	3.2	216.8	(86.8-446.6)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.3	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.5	nc	(nc-nc)	Male	5	2.0	256.3	(82.6-598.1)
<u>Leukemia</u>					Female	8	7.0	113.7	(49.0-224.1)
Male	2	3.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.5	nc	(nc-nc)	Female	14	8.9	157.0	(85.7-263.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.5	nc	(nc-nc)	Male	118	114.2	103.3	(85.5-123.8)
Female	0	1.0	nc	(nc-nc)	Female	137	130.5	105.0	(88.2-124.1)
<u>Lung and Bronchus</u>									
Male	13	15.2	85.7	(45.6-146.5)					
Female	16	19.5	81.9	(46.8-133.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sudbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	19.1	88.9	(51.8-142.4)	Male	19	12.4	153.1	(92.2-239.2)
Female	8	6.0	133.1	(57.3-262.2)	Female	9	9.1	99.2	(45.2-188.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.6	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
Female	4	2.9	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	14	10.9	127.9	(69.9-214.7)
Female	79	67.1	117.8	(93.3-146.8)	Female	10	8.0	125.3	(60.0-230.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.6	nc	(nc-nc)	Male	4	7.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	3.2	nc	(nc-nc)
Male	27	23.3	115.8	(76.3-168.5)	<u>Ovary</u>				
Female	14	20.4	68.5	(37.4-114.9)	Female	2	6.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	4.9	nc	(nc-nc)	Male	2	6.2	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	4	5.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.4	nc	(nc-nc)	Male	79	67.1	117.7	(93.1-146.6)
Female	2	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.4	nc	(nc-nc)
Male	11	10.3	107.2	(53.5-191.9)	Female	2	2.3	nc	(nc-nc)
Female	2	5.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.1	nc	(nc-nc)
Male	0	2.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	7	4.0	175.6	(70.4-361.9)
<u>Leukemia</u>					Female	10	12.0	83.2	(39.9-153.1)
Male	11	7.1	154.8	(77.2-277.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	4.8	189.3	(86.4-359.5)	Female	10	14.7	67.8	(32.5-124.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	5.5	nc	(nc-nc)	Male	235	250.5	93.8	(82.2-106.6)
Female	3	1.7	nc	(nc-nc)	Female	219	225.8	97.0	(84.6-110.7)
<u>Lung and Bronchus</u>									
Male	15	34.3	43.7	(24.5-72.1)					
Female	29	30.7	94.3	(63.2-135.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sunderland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	3.4	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	0	2.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.7	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	11	12.4	89.0	(44.3-159.2)	Female	1	1.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.7	nc	(nc-nc)
Male	1	4.3	nc	(nc-nc)	<u>Ovary</u>				
Female	3	5.1	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.8	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	12	11.3	106.6	(55.0-186.3)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.8	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<u>Leukemia</u>					Female	0	2.4	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.1	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.0	nc	(nc-nc)	Male	36	44.6	80.8	(56.6-111.8)
Female	0	0.4	nc	(nc-nc)	Female	29	47.1	61.6	(41.3-88.5)
<u>Lung and Bronchus</u>									
Male	3	5.9	nc	(nc-nc)					
Female	0	6.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sutton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	7.5	66.6	(21.4-155.3)	Male	5	5.9	85.0	(27.4-198.4)
Female	3	2.4	nc	(nc-nc)	Female	0	4.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.8	nc	(nc-nc)	Male	4	1.4	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.2	nc	(nc-nc)	Male	11	5.0	221.4	(110.4-396.1)
Female	31	31.5	98.3	(66.8-139.5)	Female	4	3.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.4	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.5	nc	(nc-nc)
Male	5	10.0	50.0	(16.1-116.8)	<u>Ovary</u>				
Female	7	8.0	87.4	(35.0-180.1)	Female	0	2.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	2.4	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	2.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	38	36.4	104.3	(73.8-143.1)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	1.9	nc	(nc-nc)
Male	5	5.1	98.0	(31.6-228.8)	Female	0	0.9	nc	(nc-nc)
Female	6	2.4	248.9	(90.9-541.8)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.3	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	8	6.5	123.0	(52.9-242.3)
Male	2	3.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.0	nc	(nc-nc)	Female	7	7.1	98.8	(39.6-203.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.7	nc	(nc-nc)	Male	112	118.8	94.3	(77.7-113.5)
Female	0	0.7	nc	(nc-nc)	Female	102	101.1	100.9	(82.3-122.5)
<u>Lung and Bronchus</u>									
Male	12	14.9	80.3	(41.4-140.2)					
Female	21	12.9	162.7	(100.7-248.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Swampscott

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	18.1	93.8	(54.6-150.2)	Male	9	11.3	79.6	(36.3-151.1)
Female	13	8.1	160.7	(85.5-274.9)	Female	16	9.8	162.6	(92.9-264.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.1	nc	(nc-nc)	Male	5	3.0	167.9	(54.1-391.8)
Female	6	3.1	196.5	(71.8-427.8)	Female	1	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	20	9.9	201.7	(123.2-311.5)
Female	82	72.1	113.7	(90.4-141.1)	Female	12	9.9	121.0	(62.5-211.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.5	nc	(nc-nc)	Male	1	6.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	3.8	nc	(nc-nc)
Male	29	21.9	132.4	(88.7-190.2)	<u>Ovary</u>				
Female	28	27.6	101.5	(67.5-146.8)	Female	6	7.2	83.2	(30.4-181.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	4.5	nc	(nc-nc)	Male	6	5.8	102.7	(37.5-223.6)
Female	1	1.6	nc	(nc-nc)	Female	5	7.9	63.6	(20.5-148.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.2	nc	(nc-nc)	Male	66	63.2	104.5	(80.8-133.0)
Female	0	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.2	nc	(nc-nc)
Male	7	9.1	77.1	(30.9-158.8)	Female	4	3.3	nc	(nc-nc)
Female	5	6.1	81.5	(26.3-190.3)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.7	nc	(nc-nc)
Male	1	2.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	11	3.4	323.5	(161.3-578.9)
<u>Leukemia</u>					Female	13	11.1	117.0	(62.3-200.2)
Male	10	6.5	153.6	(73.5-282.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	5.7	122.2	(49.0-251.8)	Female	25	16.3	153.3	(99.2-226.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	4.9	nc	(nc-nc)	Male	243	232.3	104.6	(91.9-118.6)
Female	0	2.1	nc	(nc-nc)	Female	288	264.0	109.1	(96.9-122.5)
<u>Lung and Bronchus</u>									
Male	29	32.0	90.6	(60.7-130.1)					
Female	36	37.9	95.0	(66.5-131.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Swansea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	20.0	119.7	(76.7-178.2)	Male	7	13.3	52.6	(21.1-108.3)
Female	11	7.2	152.7	(76.1-273.3)	Female	6	9.8	60.9	(22.2-132.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.7	nc	(nc-nc)	Male	0	3.4	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	Female	0	2.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	9	11.6	77.5	(35.4-147.1)
Female	60	71.6	83.8	(64.0-107.9)	Female	8	9.2	87.1	(37.5-171.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.7	nc	(nc-nc)	Male	7	8.5	82.5	(33.1-170.1)
<u>Colon / Rectum</u>					Female	3	3.6	nc	(nc-nc)
Male	18	24.4	73.9	(43.8-116.8)	<u>Ovary</u>				
Female	22	23.6	93.1	(58.3-140.9)	Female	11	6.9	160.3	(79.9-286.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	5.5	128.1	(51.3-263.9)	Male	6	6.6	91.5	(33.4-199.1)
Female	1	1.5	nc	(nc-nc)	Female	10	6.9	145.9	(69.9-268.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.6	nc	(nc-nc)	Male	94	80.2	117.2	(94.7-143.4)
Female	1	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	4.7	nc	(nc-nc)
Male	12	11.0	108.9	(56.2-190.3)	Female	4	2.7	nc	(nc-nc)
Female	5	6.0	83.6	(26.9-195.0)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.5	nc	(nc-nc)
Male	6	3.2	187.6	(68.5-408.3)	<u>Thyroid</u>				
Female	2	0.8	nc	(nc-nc)	Male	2	4.3	nc	(nc-nc)
<u>Leukemia</u>					Female	10	12.2	81.9	(39.2-150.6)
Male	4	7.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	5.1	97.4	(31.4-227.3)	Female	15	16.4	91.6	(51.2-151.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	6.0	nc	(nc-nc)	Male	270	275.6	98.0	(86.6-110.4)
Female	3	1.9	nc	(nc-nc)	Female	234	251.4	93.1	(81.5-105.8)
<u>Lung and Bronchus</u>									
Male	42	36.8	114.2	(82.3-154.4)					
Female	32	36.4	87.8	(60.0-124.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Taunton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	46	56.7	81.2	(59.4-108.3)	Male	21	37.8	55.6	(34.4-84.9)
Female	20	21.1	94.6	(57.8-146.1)	Female	21	31.3	67.1	(41.5-102.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	16	11.3	141.5	(80.8-229.8)	Male	8	9.4	85.1	(36.7-167.7)
Female	11	9.7	112.9	(56.3-202.0)	Female	6	7.6	79.0	(28.8-171.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.7	nc	(nc-nc)	Male	33	32.6	101.1	(69.6-142.0)
Female	220	218.4	100.7	(87.9-115.0)	Female	29	27.4	105.7	(70.8-151.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	12	8.8	136.3	(70.4-238.1)	Male	29	22.6	128.2	(85.8-184.1)
<u>Colon / Rectum</u>					Female	10	10.9	92.0	(44.0-169.2)
Male	67	68.0	98.5	(76.3-125.1)	<u>Ovary</u>				
Female	79	70.5	112.0	(88.7-139.6)	Female	23	21.1	109.2	(69.2-163.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	20	15.0	133.5	(81.5-206.1)	Male	34	18.3	185.3	(128.3-259.0)
Female	2	4.3	nc	(nc-nc)	Female	24	20.1	119.5	(76.6-177.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	8	5.2	153.7	(66.2-302.9)	Male	181	218.2	82.9	(71.3-95.9)
Female	6	4.3	138.5	(50.6-301.6)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	23	13.1	175.5	(111.2-263.3)
Male	33	31.0	106.4	(73.2-149.5)	Female	9	8.1	110.6	(50.5-210.1)
Female	30	18.1	165.4	(111.6-236.1)	<u>Testis</u>				
<u>Larynx</u>					Male	11	8.8	125.2	(62.4-224.0)
Male	9	8.7	103.5	(47.2-196.5)	<u>Thyroid</u>				
Female	2	2.5	nc	(nc-nc)	Male	9	12.6	71.3	(32.5-135.3)
<u>Leukemia</u>					Female	48	41.0	117.1	(86.3-155.2)
Male	19	20.8	91.2	(54.9-142.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	16.2	49.3	(21.2-97.2)	Female	42	49.0	85.7	(61.8-115.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	19	16.5	115.3	(69.4-180.0)	Male	793	771.6	102.8	(95.7-110.2)
Female	7	5.8	121.6	(48.7-250.6)	Female	794	764.3	103.9	(96.8-111.4)
<u>Lung and Bronchus</u>									
Male	133	105.8	125.7	(105.3-149.0)					
Female	123	106.8	115.1	(95.7-137.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Templeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	10.2	78.7	(33.9-155.1)	Male	6	6.2	96.3	(35.1-209.5)
Female	2	3.0	nc	(nc-nc)	Female	0	4.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.7	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	5.5	nc	(nc-nc)
Female	31	31.5	98.5	(66.9-139.9)	Female	2	3.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.2	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.5	nc	(nc-nc)
Male	9	11.9	75.4	(34.4-143.2)	<u>Ovary</u>				
Female	7	9.9	70.9	(28.4-146.1)	Female	5	2.9	170.2	(54.9-397.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	2.4	250.0	(91.3-544.3)	Male	2	3.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	33	32.6	101.1	(69.6-142.0)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.3	nc	(nc-nc)
Male	4	5.0	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.1	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
<u>Leukemia</u>					Female	3	5.8	nc	(nc-nc)
Male	5	3.6	138.9	(44.8-324.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.3	nc	(nc-nc)	Female	11	6.9	159.3	(79.4-285.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.6	nc	(nc-nc)	Male	103	126.0	81.7	(66.7-99.1)
Female	0	0.8	nc	(nc-nc)	Female	91	108.8	83.7	(67.4-102.7)
<u>Lung and Bronchus</u>									
Male	16	17.8	90.0	(51.4-146.2)					
Female	13	15.5	83.9	(44.6-143.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tewksbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	33	30.5	108.2	(74.5-152.0)	Male	26	20.5	126.8	(82.8-185.8)
Female	15	14.3	104.8	(58.6-172.9)	Female	11	18.6	59.2	(29.5-105.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	5.9	nc	(nc-nc)	Male	10	5.1	194.9	(93.3-358.5)
Female	5	5.8	86.7	(27.9-202.3)	Female	3	5.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.9	nc	(nc-nc)	Male	11	17.7	62.0	(30.9-111.0)
Female	104	135.1	77.0	(62.9-93.3)	Female	14	17.8	78.7	(43.0-132.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	5.0	140.6	(56.3-289.7)	Male	15	12.9	116.3	(65.0-191.8)
<u>Colon / Rectum</u>					Female	3	7.0	nc	(nc-nc)
Male	38	37.5	101.4	(71.7-139.2)	<u>Ovary</u>				
Female	32	47.9	66.8	(45.7-94.3)	Female	15	13.2	113.3	(63.4-186.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	8.3	72.3	(26.4-157.4)	Male	19	10.0	190.3	(114.5-297.2)
Female	2	2.9	nc	(nc-nc)	Female	16	13.8	116.1	(66.3-188.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.6	nc	(nc-nc)	Male	134	121.6	110.2	(92.4-130.6)
Female	2	2.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	7.2	69.8	(22.5-163.0)
Male	20	17.1	117.2	(71.6-181.1)	Female	8	5.7	140.8	(60.6-277.4)
Female	9	11.4	79.0	(36.1-150.0)	<u>Testis</u>				
<u>Larynx</u>					Male	5	4.1	123.1	(39.7-287.3)
Male	5	4.8	103.1	(33.2-240.6)	<u>Thyroid</u>				
Female	0	1.6	nc	(nc-nc)	Male	3	6.8	nc	(nc-nc)
<u>Leukemia</u>					Female	33	22.5	146.7	(100.9-206.0)
Male	16	11.2	143.2	(81.8-232.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	16	10.4	154.0	(88.0-250.2)	Female	38	30.2	126.0	(89.1-172.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	12	9.2	129.8	(67.0-226.7)	Male	450	421.6	106.7	(97.1-117.1)
Female	2	3.7	nc	(nc-nc)	Female	453	484.3	93.5	(85.1-102.6)
<u>Lung and Bronchus</u>									
Male	51	56.7	89.9	(66.9-118.2)					
Female	75	69.5	107.8	(84.8-135.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	4.6	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.9	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	2.7	187.5	(60.4-437.7)
Female	29	18.8	154.3	(103.3-221.6)	Female	0	2.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.7	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.9	nc	(nc-nc)
Male	8	5.5	145.4	(62.6-286.4)	<u>Ovary</u>				
Female	12	6.1	198.3	(102.3-346.4)	Female	3	1.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.3	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	0.4	nc	(nc-nc)	Male	25	18.7	133.4	(86.3-196.9)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.1	nc	(nc-nc)
Male	4	2.6	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.6	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	5	3.3	151.9	(48.9-354.4)
Male	2	1.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.3	nc	(nc-nc)	Female	5	4.3	116.0	(37.4-270.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.4	nc	(nc-nc)	Male	81	63.9	126.9	(100.7-157.7)
Female	2	0.5	nc	(nc-nc)	Female	76	64.0	118.7	(93.5-148.6)
<u>Lung and Bronchus</u>									
Male	10	8.7	114.8	(55.0-211.2)					
Female	8	8.6	93.5	(40.2-184.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tolland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	2.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	3.9	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.4	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	11.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	7.8	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	1	1.7	nc	(nc-nc)					
Female	0	1.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Topsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	6.6	136.5	(62.3-259.0)	Male	8	4.4	181.2	(78.0-357.0)
Female	3	3.2	nc	(nc-nc)	Female	3	3.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.3	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
Female	32	28.0	114.3	(78.2-161.3)	Female	2	3.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.5	nc	(nc-nc)
Male	6	8.4	71.7	(26.2-156.1)	<u>Ovary</u>				
Female	13	11.2	115.6	(61.5-197.8)	Female	2	2.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.8	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	38	26.6	143.1	(101.2-196.4)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.6	nc	(nc-nc)
Male	3	3.7	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
Female	0	2.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.8	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	4.2	nc	(nc-nc)
Male	4	2.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	2.3	nc	(nc-nc)	Female	7	5.9	118.6	(47.5-244.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.0	nc	(nc-nc)	Male	114	91.6	124.4	(102.6-149.5)
Female	0	0.8	nc	(nc-nc)	Female	90	102.8	87.6	(70.4-107.6)
<u>Lung and Bronchus</u>									
Male	11	12.2	90.5	(45.1-162.0)					
Female	11	14.3	77.0	(38.4-137.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Townsend

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	6.9	158.6	(79.1-283.9)	Male	4	5.6	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)	Female	4	4.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.8	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	4.8	105.1	(33.9-245.2)
Female	28	34.1	82.1	(54.5-118.6)	Female	3	3.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.4	nc	(nc-nc)	Male	1	3.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.5	nc	(nc-nc)
Male	9	9.4	95.6	(43.6-181.6)	<u>Ovary</u>				
Female	10	8.7	115.3	(55.2-212.0)	Female	6	3.1	195.8	(71.5-426.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.2	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	4	2.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.9	nc	(nc-nc)	Male	22	32.5	67.6	(42.4-102.4)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.8	nc	(nc-nc)
Male	4	4.8	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.5	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
<u>Leukemia</u>					Female	4	6.7	nc	(nc-nc)
Male	1	3.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	2.1	nc	(nc-nc)	Female	6	7.6	78.6	(28.7-171.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.6	nc	(nc-nc)	Male	101	110.1	91.7	(74.7-111.4)
Female	2	0.8	nc	(nc-nc)	Female	95	107.4	88.4	(71.5-108.1)
<u>Lung and Bronchus</u>									
Male	17	13.5	125.5	(73.1-200.9)					
Female	14	13.4	104.7	(57.2-175.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Truro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	3.8	130.6	(42.1-304.9)	Male	1	2.4	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	2	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
Female	18	11.2	161.4	(95.6-255.1)	Female	0	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.6	nc	(nc-nc)
Male	6	4.4	135.1	(49.3-294.1)	<u>Ovary</u>				
Female	1	3.5	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.1	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	13	16.7	77.6	(41.3-132.7)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.9	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.6	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.7	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.1	nc	(nc-nc)	Male	45	52.7	85.5	(62.3-114.4)
Female	0	0.3	nc	(nc-nc)	Female	38	38.5	98.7	(69.8-135.4)
<u>Lung and Bronchus</u>									
Male	2	7.4	nc	(nc-nc)					
Female	5	5.8	85.9	(27.7-200.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tyngsborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	8.0	212.6	(123.8-340.4)	Male	7	6.5	107.7	(43.1-221.8)
Female	6	3.5	173.7	(63.4-378.0)	Female	3	6.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.1	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.6	88.9	(28.7-207.5)
Female	40	43.4	92.2	(65.9-125.6)	Female	5	4.8	103.8	(33.5-242.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.8	nc	(nc-nc)	Male	5	4.5	109.9	(35.4-256.5)
<u>Colon / Rectum</u>					Female	2	2.0	nc	(nc-nc)
Male	14	11.2	124.8	(68.1-209.3)	<u>Ovary</u>				
Female	8	12.1	66.1	(28.5-130.3)	Female	2	4.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.6	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	7	3.3	215.3	(86.2-443.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.0	nc	(nc-nc)	Male	22	38.7	56.9	(35.7-86.2)
Female	2	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.1	nc	(nc-nc)
Male	3	5.6	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Female	3	3.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.7	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
<u>Leukemia</u>					Female	8	8.7	91.9	(39.6-181.1)
Male	4	3.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	2.9	174.0	(56.1-406.0)	Female	3	9.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	9	3.1	288.6	(131.7-547.8)	Male	126	129.3	97.4	(81.2-116.0)
Female	1	1.0	nc	(nc-nc)	Female	131	141.1	92.8	(77.6-110.2)
<u>Lung and Bronchus</u>									
Male	20	15.7	127.2	(77.7-196.5)					
Female	18	17.8	101.1	(59.9-159.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tyringham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	2	3.0	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	7	3.4	204.2	(81.8-420.8)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.4	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.2	nc	(nc-nc)	Male	16	10.9	146.4	(83.6-237.7)
Female	0	0.1	nc	(nc-nc)	Female	4	11.1	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	3	1.6	nc	(nc-nc)					
Female	0	1.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Upton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	5.7	123.2	(49.3-253.8)	Male	1	4.2	nc	(nc-nc)
Female	7	1.9	370.9	(148.6-764.1)	Female	2	3.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.3	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
Female	28	25.1	111.5	(74.1-161.1)	Female	0	2.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.1	nc	(nc-nc)
Male	4	7.6	nc	(nc-nc)	<u>Ovary</u>				
Female	3	6.7	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.6	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	4	1.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	25	24.1	103.8	(67.2-153.3)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.4	nc	(nc-nc)
Male	2	3.6	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.0	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	8	4.9	164.7	(70.9-324.5)
Male	5	2.2	222.5	(71.7-519.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.6	nc	(nc-nc)	Female	9	5.5	163.6	(74.6-310.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.0	nc	(nc-nc)	Male	86	84.2	102.1	(81.7-126.1)
Female	0	0.6	nc	(nc-nc)	Female	88	79.8	110.3	(88.5-135.9)
<u>Lung and Bronchus</u>									
Male	14	10.9	128.8	(70.4-216.2)					
Female	7	10.0	70.2	(28.1-144.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Uxbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	12.2	122.6	(68.6-202.3)	Male	4	8.6	nc	(nc-nc)
Female	11	3.9	279.6	(139.4-500.3)	Female	3	6.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.7	nc	(nc-nc)	Male	4	2.1	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	11	7.5	147.2	(73.4-263.5)
Female	47	44.9	104.6	(76.9-139.2)	Female	7	5.3	131.9	(52.8-271.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.9	nc	(nc-nc)	Male	5	5.3	94.2	(30.4-219.9)
<u>Colon / Rectum</u>					Female	1	2.1	nc	(nc-nc)
Male	17	15.4	110.4	(64.3-176.8)	<u>Ovary</u>				
Female	12	13.4	89.4	(46.1-156.1)	Female	5	4.2	119.9	(38.6-279.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.3	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	1.2	nc	(nc-nc)	Male	57	46.8	121.7	(92.2-157.7)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.9	nc	(nc-nc)
Male	5	7.0	71.2	(22.9-166.1)	Female	1	1.5	nc	(nc-nc)
Female	6	3.6	165.5	(60.4-360.2)	<u>Testis</u>				
<u>Larynx</u>					Male	6	2.0	298.0	(108.8-648.7)
Male	1	1.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.5	nc	(nc-nc)	Male	5	3.0	168.5	(54.3-393.1)
<u>Leukemia</u>					Female	7	9.0	77.7	(31.1-160.1)
Male	2	4.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	3.2	156.6	(50.5-365.4)	Female	14	9.6	145.5	(79.5-244.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.9	nc	(nc-nc)	Male	197	170.3	115.7	(100.1-133.0)
Female	0	1.1	nc	(nc-nc)	Female	175	151.8	115.3	(98.8-133.7)
<u>Lung and Bronchus</u>									
Male	29	22.7	127.9	(85.6-183.7)					
Female	31	20.4	151.7	(103.1-215.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wakefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	28.0	92.7	(60.6-135.9)	Male	21	18.4	113.8	(70.4-174.0)
Female	9	11.3	80.0	(36.5-151.8)	Female	19	15.2	124.6	(75.0-194.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	5.3	94.4	(30.4-220.4)	Male	5	4.7	107.0	(34.5-249.8)
Female	3	4.6	nc	(nc-nc)	Female	5	4.0	124.1	(40.0-289.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	15	16.1	93.0	(52.0-153.4)
Female	135	110.6	122.1	(102.3-144.5)	Female	19	14.2	133.8	(80.5-208.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	4.2	nc	(nc-nc)	Male	10	11.3	88.4	(42.3-162.7)
<u>Colon / Rectum</u>					Female	3	5.6	nc	(nc-nc)
Male	29	34.5	84.0	(56.3-120.7)	<u>Ovary</u>				
Female	33	37.6	87.7	(60.4-123.2)	Female	12	10.8	111.5	(57.6-194.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	7.3	124.0	(56.6-235.4)	Male	7	9.1	77.0	(30.8-158.6)
Female	4	2.3	nc	(nc-nc)	Female	6	10.8	55.8	(20.4-121.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.3	nc	(nc-nc)	Male	105	103.7	101.2	(82.8-122.5)
Female	2	1.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	6.6	76.2	(24.6-177.9)
Male	13	15.0	86.6	(46.1-148.2)	Female	3	4.4	nc	(nc-nc)
Female	6	9.2	65.0	(23.7-141.5)	<u>Testis</u>				
<u>Larynx</u>					Male	6	3.7	160.5	(58.6-349.3)
Male	5	4.2	118.6	(38.2-276.7)	<u>Thyroid</u>				
Female	2	1.3	nc	(nc-nc)	Male	7	6.0	116.6	(46.7-240.2)
<u>Leukemia</u>					Female	18	19.0	94.5	(56.0-149.4)
Male	10	10.4	96.2	(46.1-177.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	8.2	122.5	(58.6-225.3)	Female	18	24.9	72.4	(42.9-114.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	8.1	nc	(nc-nc)	Male	364	375.3	97.0	(87.3-107.5)
Female	3	3.0	nc	(nc-nc)	Female	400	390.6	102.4	(92.6-112.9)
<u>Lung and Bronchus</u>									
Male	44	50.6	87.0	(63.2-116.8)					
Female	49	55.7	88.0	(65.1-116.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wales

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.2	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	7	8.3	84.6	(33.9-174.3)	Female	0	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	3	2.7	nc	(nc-nc)	<u>Ovary</u>				
Female	3	1.9	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	0.7	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	10.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.4	nc	(nc-nc)
Male	2	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.6	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.5	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.8	nc	(nc-nc)	Male	25	33.1	75.4	(48.8-111.3)
Female	0	0.2	nc	(nc-nc)	Female	28	25.8	108.4	(72.0-156.6)
<u>Lung and Bronchus</u>									
Male	3	4.3	nc	(nc-nc)					
Female	6	3.3	179.9	(65.7-391.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;